Centessa Pharmaceuticals (NASDAQ:CNTA) Sees Unusually-High Trading Volume – Should You Buy?

Shares of Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) saw unusually-strong trading volume on Thursday . Approximately 1,975,302 shares changed hands during mid-day trading, a decline of 5% from the previous session’s volume of 2,074,203 shares.The stock last traded at $39.8250 and had previously closed at $39.87.

Analysts Set New Price Targets

Several research analysts recently weighed in on CNTA shares. Needham & Company LLC cut shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, March 31st. B. Riley Financial cut shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a research report on Monday, April 20th. Lifesci Capital cut shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 1st. Finally, Stephens cut shares of Centessa Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, March 31st. Four research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Centessa Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $41.33.

Centessa Pharmaceuticals Trading Up 0.1%

The stock has a market capitalization of $6.17 billion, a P/E ratio of -22.30 and a beta of 1.11. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.23. The stock’s fifty day moving average price is $39.65 and its two-hundred day moving average price is $31.11.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.14). Equities research analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current year.

Insider Activity

In other news, insider Karen M. Anderson sold 41,076 shares of the firm’s stock in a transaction that occurred on Thursday, March 26th. The shares were sold at an average price of $30.12, for a total value of $1,237,209.12. Following the transaction, the insider owned 62,085 shares in the company, valued at approximately $1,870,000.20. This trade represents a 39.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.09% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Virtus Investment Advisers LLC grew its holdings in shares of Centessa Pharmaceuticals by 6.2% in the fourth quarter. Virtus Investment Advisers LLC now owns 10,034 shares of the company’s stock worth $251,000 after purchasing an additional 583 shares during the last quarter. Coastal Bridge Advisors LLC grew its holdings in shares of Centessa Pharmaceuticals by 7.1% in the fourth quarter. Coastal Bridge Advisors LLC now owns 14,033 shares of the company’s stock worth $351,000 after purchasing an additional 931 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Centessa Pharmaceuticals by 26.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,688 shares of the company’s stock worth $117,000 after purchasing an additional 979 shares during the last quarter. TD Waterhouse Canada Inc. bought a new position in shares of Centessa Pharmaceuticals in the fourth quarter worth approximately $25,000. Finally, Wells Fargo & Company MN grew its holdings in shares of Centessa Pharmaceuticals by 42.4% in the fourth quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock worth $85,000 after purchasing an additional 1,008 shares during the last quarter. Institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.